GlassScriptPhysician profile
Lisa A Bearden
NPI 1558560102
$3,013.92
in general payments reported to CMS, 2019-2025
26 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $65.22 · 2021: $700 · 2022: $223 · 2023: $425 · 2024: $995 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921 · Travel and Lodging: $761 · Education: $99.00 · Consulting Fee: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.17 |
| Travel and Lodging | $761.28 |
| Education | $99.00 |
| Consulting Fee | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $853.01 | 2024 | Gelpoint V-Path |
| Abbvie INC. | $603.56 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $293.70 | 2019-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Novasure, Acessa Provu System |
| Mayne Pharma Commercial LLC | $123.88 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.21 | 2019-2023 | |
| Exeltis, USA INC. | $110.01 | 2021-2025 | Slynd |
| Astellas Pharma US INC | $99.00 | 2025 | |
| Organon LLC | $84.93 | 2021-2024 | Nexplanon |
| Therapeuticsmd, INC. | $76.79 | 2019-2022 | |
| Pfizer INC. | $68.59 | 2019-2024 | |
| Evofem Biosciences, INC. | $60.07 | 2021 | |
| Sumitomo Pharma America, INC. | $56.89 | 2023-2024 | Myfembree |
| Mylan Pharmaceuticals INC. | $55.67 | 2021 | |
| Medtronic, INC. | $55.01 | 2023-2024 | Interstim, Ligasure |
| Allergan, INC. | $50.66 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $48.45 | 2025 | Femlyv, Intrarosa |
| Shield Therapeutics INC | $45.30 | 2023-2025 | Accrufer |
| Novo Nordisk INC | $40.54 | 2023 | Wegovy |
| Currax Pharmaceuticals LLC | $33.68 | 2021-2022 | |
| Lilly USA, LLC | $29.72 | 2024-2025 | Zepbound, Mounjaro |
| Coopersurgical, INC. | $25.00 | 2023 | Summit Doppler |
| Meditrina | $20.89 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.88 | 2023 | Trulance, Xifaxan |
| Galderma Laboratories, L.P. | $13.79 | 2020 | |
| Glaxosmithkline, LLC. | $13.65 | 2025 | Ojjaara |
| Myovant Sciences INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Bearden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.